DEXTROTHYROXINE SODIUM ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H10I4NO4.Na
Molecular Weight	798.8518
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEXTROTHYROXINE SODIUM ANHYDROUS

Structure Search

SMILES

[Na+].N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O

InChI

InChIKey=YDTFRJLNMPSCFM-UTONKHPSSA-M

InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1

HIDE SMILES / InChI

Description
Sources: https://www.drugbank.ca/drugs/DB00509
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68003918

Dextrothyroxine is the dextrorotary isomer of the synthetic thyroxine. It is an antihyperlipidemic agent. The mechanism of action is not completely understood, but dextrothyroxine apparently acts in the liver to stimulate formation of low-density lipoprotein (LDL) and, to a much greater extent, to increase catabolism of LDL. This leads to increased excretion of cholesterol and bile acids via the biliary route into the feces, with a resulting reduction in serum cholesterol and LDL. Dextrothyroxine has no significant effect on high-density lipoproteins (HDL). Inherently, it will also bind to thyroid receptors and as it is a prohormone, it will bind as a substrate to iodide peroxidase.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thyroid hormone receptor 6 Target ID: CHEMBL2111462 Sources: https://www.drugbank.ca/drugs/DB00509	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypercholesterolemia 47 Sources: https://www.drugbank.ca/drugs/DB00509	Primary		Approved 8429	CHOLOXIN Approved Use Used to lower high cholesterol levels in the blood. Launch Date 1967

T_1/2

Value	Dose	Co-administered	Analyte	Population
6 day REVIEW https://pubmed.ncbi.nlm.nih.gov/363332/	6 mg 1 times / day unknown, oral dose: 6 mg route of administration: Oral experiment type: UNKNOWN co-administered:		LEVOTHYROXINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% REVIEW https://pubmed.ncbi.nlm.nih.gov/363332/	6 mg 1 times / day unknown, oral dose: 6 mg route of administration: Oral experiment type: UNKNOWN co-administered:		LEVOTHYROXINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/	unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/	Disc. AE: Loss of control of diabetes, Acidosis... Other AEs: Blood cholesterol decreased... AEs leading to discontinuation/dose reduction: Loss of control of diabetes (8 patients) Acidosis (1 patient) Hypoglycemic reaction (2 patients) Other AEs: Blood cholesterol decreased (18 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/

AEs

AE	Significance	Dose	Population
Acidosis	1 patient Disc. AE	8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/	unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/
Blood cholesterol decreased	18 patients	8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/	unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/
Hypoglycemic reaction	2 patients Disc. AE	8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/	unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/
Loss of control of diabetes	8 patients Disc. AE	8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/	unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/14204552/

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-047088	http://www.3bsc.com/index/pro_info.php?id=83740
AA Blocks	AA006VP2	https://www.aablocks.com/goods/Goods/detail?id=AA006VP2
AEchem Scientific Corp., USA	AE029677	http://www.aechemsc.com/info_products/AE029677.php
AHH Chemical co.,ltd	MB-00564	http://www.ahhchemical.com/product/MB-00564.html
AHH Chemical co.,ltd	MT-50746	http://www.ahhchemical.com/product/MT-50746.html
Aaron Chemicals	AR006WGU	http://www.aaronchem.com/51-49-0
Achemtek	0104-042131	http://www.achemtek.com/51-49-0
Alichem	19113114	http://www.alichem.com/en/products/51-49-0.html
Angene	AGN-PC-0OBILQ	http://www.angenechemical.com/productshow/AGN-PC-0OBILQ.html
Anward	ANW-63155	http://www.anward.com/pro_result/49606
Aurora Fine Chemicals LLC	A17.915.702	http://online.aurorafinechemicals.com/info?ID=A17.915.702
BLD Pharm	BD33885	http://www.bldpharm.com/products/51-49-0.html
Chemenu	CM129121	http://www.chemenu.com/products/CM129121
Chemspace	CSSB00000092231	https://chem-space.com/CSSB00000092231
DC Chemicals	DC31645	http://www.dcchemicals.com//product_show-Biotirmone.html
Glentham Life Sciences	GM9007	http://www.glentham.com/products/product/GM9007/
LGC Standards	LGCFOR1813.01	https://www.lgcstandards.com/US/en/p/LGCFOR1813.01
LGC Standards	MM1813.01	https://www.lgcstandards.com/US/en/p/MM1813.01
Lab Network	LN00337290	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00337290
MuseChem	R046180	https://www.musechem.com/product/R046180.html
OChem	11916	http://www.ocheminc.com/index.php?act=psearch&pid=051T490
Sigma-Aldrich	R751804_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/r751804
Sigma-Aldrich	T34908_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/t34908?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S525805	http://www.smolecule.com/products/s525805
Smolecule	S793415	https://www.smolecule.com/products/s793415
THE BioTek	bt-267396	https://www.thebiotek.com/product/inhibitors/bt-267396
abcr GmbH	AB142563	http://www.abcr.com/shop/en/AB142563
eNovation Chemicals	D673948	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673948
eNovation Chemicals	D765759	https://www.enovationchem.com/ProductDetails.asp?ProductID=D765759
eNovation Chemicals	D957539	https://www.enovationchem.com/ProductDetails.asp?ProductID=D957539
iChemical	EBD2197960	http://www.ichemical.com/products/51-49-0.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Inhibition of the activity of the native gamma-aminobutyric acid A receptor by metabolites of thyroid hormones: correlations with molecular modeling studies.	2004 Apr 9	15033424
9 years follow-up of a patient with pituitary form of resistance to thyroid hormones (PRTH): comparison of two treatment periods of D-thyroxine and triiodothyroacetic acid (TRIAC).	2009 Oct	20020587
Enatioselective quantitative separation of D- and L-thyroxine by molecularly imprinted micro-solid phase extraction silver fiber coupled with complementary molecularly imprinted polymer-sensor.	2010 Jun 25	20483419
Layer-by-layer assembled molecularly imprinted polymer modified silver electrode for enantioselective detection of D- and L-thyroxine.	2010 Nov 29	21035598

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

The relative binding affinities of liothyronine (L-T3), levothyroxine (L-T4), D-triiodothyronine (D-T3), and dextrothyroxine (D-T4) were measured in vitro. Solubilized nuclear receptors were prepared from rat anterior pituitaries. L-T3 had the highest binding for the nuclear receptor (taken as 100%). L-T4 and D-T3 binded to the nuclear receptor with similar affinities (11% and 13%, respectively), while the affinity of D-T4 represents only 3% that of L-T3.

Name

Type

Language

DEXTROTHYROXINE SODIUM ANHYDROUS

Common Name

English

dextrothyroxine sodium [INN]

Common Name

English

D-THYROXINE SODIUM SALT

Common Name

English

D-THYROXINE SODIUM SALT [MI]

Common Name

English

ANHYDROUS DEXTROTHYROXINE SODIUM

Common Name

English

Dextrothyroxine sodium [WHO-DD]

Common Name

English

SODIUM DEXTROTHYROXINE

Common Name

English

ANHYDROUS DEXTROTHYROXINE SODIUM [MART.]

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID50929656